Targeting Microbiota 2020 will be a Virtual and In-Person Congress

We have been closely following updates and evolving guidance from local, national and global agencies for COVID-19. There is still much uncertainty around the coronavirus, and how long our communities may be impacted by the pandemic, but it seems certain that decisions about how we work, travel and gather together will continue to be influenced for weeks and months still to come. Today, we have made the decision to combine In-Person and Virtual conference.


If you cannot attend in-person or virtual due to the restriction and time zone difference, you can access on-demand videos to this entire event, including synced audio/video and slides.

All posters will be in PDF format. You can visit them, upload and interact directly with the poster presenter. You can also exchange with speakers via direct or private exchange during the conference.

We will keep you informed of any new decision.

Welcome to Targeting Microbiota 2020

President Targeting Microbiota 2020Dear colleagues,

On behalf of the International Society of Microbiota, we are pleased to inform you that the 8th World Congress on Targeting Microbiota will be organized at UNESCO World Heritage Centre - Paris, France, on
October 21-23, 2020. 


Psychotropic Drugs and Microbiota - Important and Little Known Interaction

Dr. Łoniewsk Targeting Microbiota 2019

During the 7th World Congress on Targeting Microbiota scheduled on October 10-11, 2019 at the ParkInn Hotel - Krakow, Poland, Dr. Igor Loniewski from Pomeranian Medical University, Poland will give a presentation entitled "Psychotropic Drugs and Microbiota - Important and Little Known Interaction".

Summary of presentation: "Alterations in intestinal microbiota have been associated with the use of antidepressants. Antidepressants differ in mechanisms of their antibacterial activity; for example, they affect cellular respiration, whereby Monoamine Oxidase Inhibitors (MAOIs) can disturb bacterial cell-wall synthesis. Tricyclic antidepressants (TCAs) inhibit DNA gyrase activity and plasmid DNA replication. Selective serotonin reuptake inhibitors (SSRIs) inhibit bacterial efflux pumps. Escitalopram has also antibacterial activity, moreover it was also shown that a six-week escitalopram treatment in a psychiatric hospital setting resulted in increased alpha biodiversity in fecal microbiota Antipsychotic treatment-related microbiome alterations potentially result in body weight gain and metabolic disturbances. Inflammation and resting metabolic rate suppression seem to play crucial roles in the development of metabolic disorders. However in our study we found that the microbiota of schizophrenia patients is highly individual but can be divided into different taxonomical and functional clusters and it does not change following six weeks of olanzapine therapy. Microbiota did not affect either the weight gain observed in women or the effectiveness of olanzapine therapy."


For more information:


Microbiota World Congress 2019

bouton more pictures

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next